---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-281672"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:57:09.331636+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CG Oncology Q3 net loss $43.8M ($0.57/share); initiates BLA for cretostimogene

## Summary
- Net loss of $43.8M ($0.57 per share) for Q3 2025 vs $20.4M ($0.30) in Q3 2024.
- Cash, cash equivalents and marketable securities $680.3M, sufficient to fund operations into H1 2028.
- Initiated rolling BLA submission to FDA for cretostimogene monotherapy in HR BCG-unresponsive NMIBC.
- R&D expenses $27.9M (up 42% YoY), G&A $23.3M (up 168% YoY) driven by clinical trials and headcount.
- Completed enrollment of Phase 3 PIVOT-006 trial in IR NMIBC 10 months ahead of schedule.

## SEC filing metadata
- accession: 0001193125-25-281672
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000119312525281672/0001193125-25-281672-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000119312525281672/ck0001991792-20251114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-281672
- JSON: https://secwatch.observer/filing/0001193125-25-281672.json
- Plain text: https://secwatch.observer/filing/0001193125-25-281672.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.